Breast Protocol - NSABP B-55

NSABP B-55

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High-Risk HER2 Negative Adjuvant Chemotherapy.